Medicaid Coverage Mandated for Whole Genome Sequencing for Children with Rare Diseases.
This Act clarifies that the Medicaid program must cover whole genome and whole exome sequencing for children suspected of having rare genetic disorders or conditions of unknown origin. This change aims to speed up diagnosis and treatment for vulnerable children and their families. Crucially, payments for these advanced diagnostic tests must be processed separately, ensuring better access and reducing administrative denials.
Key points
Medicaid is required to cover whole genome and whole exome sequencing (WGS/WES) as a first-tier test for children with suspected genetic disorders, developmental delays, or congenital anomalies.
Coverage includes sequencing the DNA of first-degree biological relatives if necessary for the child's diagnosis or treatment.
Payments for WGS/WES must be made separately and cannot be bundled with other medical services, aiming to improve reimbursement and access.
The Department of Health and Human Services (HHS) must conduct outreach and monitor implementation to address potential barriers like prior authorization requirements.
Status:
Introduced
Civic Will
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.